Chronic Kidney Disease Treatment Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Product Type (Diagnosis, Treatment, Dialysis, Others), By End User (Hospital, Diagnostic Laboratories, Other), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 37.07 Billion
CAGR (2026-2031)	4.71%
Fastest Growing Segment	Diagnosis Segment
Largest Market	North America
Market Size (2031)	USD 48.86 Billion

Market Overview

The Global Chronic Kidney Disease Treatment Market will grow from USD 37.07 Billion in 2025 to USD 48.86 Billion by 2031 at a 4.71% CAGR. Chronic Kidney Disease treatment encompasses a range of therapeutic interventions designed to manage renal function decline, including pharmacological therapies, dialysis, and kidney transplantation. The market is primarily driven by the escalating global incidence of lifestyle-related comorbidities such as diabetes and hypertension, alongside an aging demographic that is increasingly susceptible to renal insufficiency. According to the International Society of Nephrology, in 2024, more than 850 million individuals worldwide were estimated to be affected by some form of kidney disease, underscoring the critical demand for effective medical solutions.

However, the market faces a significant restraint regarding the prohibitive costs associated with long-term renal care and advanced replacement therapies. In many developing regions, the lack of comprehensive reimbursement frameworks and insufficient healthcare infrastructure prevents a large segment of the population from accessing life-saving treatments. These financial barriers and economic disparities constitute a primary challenge that could substantially impede the broader expansion of the global treatment sector.

Key Market Drivers

The Increasing Incidence of Diabetes-Related Nephropathy is a primary force expanding the Global Chronic Kidney Disease Treatment Market. High blood glucose levels in diabetic patients progressively damage the renal filtration system, leading to diabetic kidney disease, which accounts for a substantial proportion of end-stage renal disease cases globally. This causal link ensures a continuous and growing influx of patients requiring chronic management and therapeutic intervention. According to the International Diabetes Federation, April 2025, in the 'IDF Diabetes Atlas 11th Edition', it was reported that 11.1% of the adult population worldwide is currently living with diabetes, creating a massive reservoir of patients at elevated risk for developing renal complications.

Advancements in Novel Pharmacological Therapies and Biologics are fundamentally reshaping market dynamics by offering treatments that delay disease progression rather than merely managing symptoms. The commercial success of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors has injected substantial revenue into the sector and improved patient outcomes. According to Boehringer Ingelheim, April 2025, in the '2024 results research and development investment rise' announcement, the company reported that sales of Jardiance, a treatment indicated for chronic kidney disease, rose 14.6% to EUR 8.4 billion. This surge in pharmacological adoption is critical given the scarcity of curative options; for instance, according to the American Kidney Fund, in 2024, only 28,492 patients in the United States were able to receive a kidney transplant, underscoring the vital reliance on effective pharmaceutical and dialysis maintenance.

Download Free Sample Report

Key Market Challenges

The prohibitive costs associated with long-term renal care and advanced replacement therapies serve as a critical barrier hampering the growth of the Global Chronic Kidney Disease Treatment Market. Although the incidence of renal insufficiency is rising, the high expense of treatments like dialysis and transplantation prevents a substantial portion of the patient population from accessing necessary care. This issue is particularly acute in developing regions where healthcare infrastructure is insufficient and comprehensive reimbursement models are absent. Consequently, the market is unable to capture the full economic potential of the growing patient base, as financial constraints limit the adoption of therapeutic interventions.

According to the International Society of Nephrology, in 2024, full public funding for hemodialysis was available in only 28% of participating low and lower-middle-income countries. This statistic highlights the severe economic disparity that restricts market penetration in these regions. Without adequate funding mechanisms, the clinical need for kidney disease management cannot be translated into effective commercial demand, thereby stalling broader sector expansion and confining revenue growth primarily to developed nations with established healthcare coverage.

Key Market Trends

The Shift Toward Home-Based Dialysis Through Portable and Wearable Technologies is revolutionizing the market by addressing the logistical and financial burdens of traditional in-center treatments. This trend is characterized by the development of user-friendly, connected dialysis systems that allow patients to manage end-stage renal disease in their own residences, thereby improving quality of life and reducing exposure to hospital-acquired infections. The transition is further supported by favorable reimbursement policies and clinical advocacy for remote care modalities which alleviate the strain on overburdened healthcare facilities. Demonstrating the growing penetration of this treatment delivery model, according to DaVita, May 2025, in the '2024 Community Care' report, more than 15% of the company’s patients dialyzed in the comfort of their home, reflecting a sustained structural move towards decentralized renal replacement therapies.

The Integration of Artificial Intelligence for Early Disease Detection and Risk Stratification is establishing a new paradigm in precision renal care, moving the sector from reactive management to predictive intervention. By leveraging advanced machine learning algorithms and novel biomarkers, clinicians can now identify patients at high risk of rapid kidney function decline much earlier than traditional methods allow, facilitating timely therapeutic interventions that can delay dialysis dependency. This technological adoption is being validated by increasing payer coverage and commercial uptake of prognostic testing platforms. Highlighting this commercial trajectory, according to Renalytix, March 2025, in the 'Half-year Report', commercial insurance reimbursed testing revenue increased 28% compared to the prior period, underscoring the expanding market value and clinical integration of AI-driven diagnostic tools.

Segmental Insights

The Diagnosis segment represents the fastest-growing component of the Global Chronic Kidney Disease Treatment Market, driven by an increasing clinical emphasis on early detection to delay disease progression. This expansion is primarily supported by the rising prevalence of diabetes and hypertension, which necessitates frequent patient screening. Furthermore, updated guidelines from organizations such as the National Kidney Foundation encourage widespread testing, prompting healthcare providers to adopt blood and urine analysis proactively. Consequently, the demand for diagnostic tools is accelerating as medical professionals prioritize identifying renal impairment before complex interventions become necessary.

Regional Insights

North America leads the global chronic kidney disease treatment market, driven by substantial healthcare expenditure and established medical infrastructure. The region benefits from the active presence of major pharmaceutical developers focusing on new therapeutic options. Regulatory support from the U.S. Food and Drug Administration ensures the timely approval of treatments, while the Centers for Medicare & Medicaid Services offer reimbursement frameworks that facilitate patient access to care. These elements, combined with high diagnosis rates, secure the position of North America as the primary market for kidney disease management.

Recent Developments

• In October 2025, Vertex Pharmaceuticals disclosed its plan to submit a biologics license application to the U.S. Food and Drug Administration for povetacicept. The company aimed to seek accelerated approval for the investigational drug as a treatment for IgA nephropathy, a serious chronic kidney disease. This regulatory step followed positive clinical data demonstrating that the dual BAFF/APRIL antagonist significantly reduced proteinuria and stabilized glomerular filtration rates in patients. The submission underscored the company's progress in bringing disease-modifying therapies to market for rare renal conditions with high unmet medical needs.
• In April 2025, Novartis announced a definitive agreement to acquire Regulus Therapeutics to enhance its pipeline of medicines for kidney diseases. The Swiss pharmaceutical company agreed to pay $800 million in upfront cash to obtain rights to farabursen, a Phase 3-ready oligonucleotide inhibitor targeting microRNA-17. This therapeutic candidate was being developed for the treatment of autosomal dominant polycystic kidney disease, a genetic disorder with limited treatment options. The acquisition, which included potential milestone payments valuing the deal at up to $1.7 billion, reflected the company's strategic expansion into high-value renal indications.
• In September 2024, Boehringer Ingelheim confirmed the recruitment of the first participants for its Phase 3 EASi-KIDNEY trial. This global study was established to evaluate the safety and efficacy of vicadrostat, a novel aldosterone synthase inhibitor, when administered in combination with the SGLT2 inhibitor empagliflozin. The trial aimed to enroll approximately 11,000 adults with established chronic kidney disease to determine if the combination therapy could slow disease progression more effectively than standard treatments. This research initiative highlighted the company's commitment to developing comprehensive care solutions for patients suffering from progressive renal conditions.
• In June 2024, Novo Nordisk presented detailed results from the Phase 3 FLOW trial regarding the use of semaglutide in patients with type 2 diabetes and chronic kidney disease. The data, shared at a major scientific congress, revealed that the once-weekly injectable treatment reduced the risk of kidney disease progression and major cardiovascular events by 24% compared to placebo. Following this significant clinical milestone, the company submitted an application to regulatory authorities to expand the product's label, aiming to provide a new therapeutic option for managing renal outcomes in this specific patient population.

Key Market Players

• AbbVie Inc.
• Amgen Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Merck & Co. Inc.
• Pfizer Inc.
• Sysmex Corporation
• Teva Pharmaceutical Industries Ltd

By Product Type	By End User	By Region
Diagnosis Treatment Dialysis Others	Hospital Diagnostic Laboratories Other	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Chronic Kidney Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Chronic Kidney Disease Treatment Market , By Product Type:

• Diagnosis
• Treatment
• Dialysis
• Others

• Chronic Kidney Disease Treatment Market , By End User:

• Hospital
• Diagnostic Laboratories
• Other

• Chronic Kidney Disease Treatment Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE